Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors

Cancer Biology and Therapy

Volumn 7, Issue 4, 2008, Pages 523-531

  Ouaissi M ^a,b,c   Cabral, S ^d,e   Tavares, J ^d,e   Cordeiro Da Silva, A ^d,e   Mathieu Daude, F ^c   Mas, E ^b   Bernard, J P ^b   Sastre, B ^a   Lombardo, D ^b   Ouaissi, Ali ^c,e  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Apoptosis; HDAC inhibitors; HDACs; Nicotinamide; Pancreatic cancer cells; RT PCR; Sirtinol; SIRTs; TSA

Indexed keywords

DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; PHOSPHATIDYLSERINE; SIRTINOL; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG INHIBITION; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE; PANCREAS ADENOCARCINOMA; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 45349083716     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.4.5480     Document Type: Article

References (30)

1. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59:1071-89.
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
3. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65:2344-52.
4. Cascallo M, Calbo J, Capella G, Fillat C, Pastro Anglada M, Mazo A. Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. Oncology 2005; 68:179-89.
5. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, hruban RH, Yeao CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731-4.
6. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84:253-62.
7. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K, Scarpa A. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 1999; 59:1308-14.
8. (WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61:8830-7.
9. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000; 19:1176-9.
10. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999; 9:40-8.
11. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer. Int J Oncol 2004; 25:1509-19.
12. Ouaissi M, Ouaissi A. Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotech 2006; 13474:1-10.
13. Garcia Morales P, Gomez Martinez A, Carrato A, Martinez Lacaci, Barbera VM, Soto JL, Carrasco G, Menedez Gutierrez MP, Castro Galache MD, Ferragut JA, Saceda M. histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol cancer Ther 2005; 4:1222-30.
14. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121:656-65.
15. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. CancerChemother Pharmacol 2001; 48:17-9.
16. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Klöppel G, Kalthoff H, Ungefroren H, Löhr M, Scarpa A.Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439:798-802.
17. Fujii Y, Sekiguchi M, Shiroko Y, Shimuzu H, Sugawara I, Hasumi K, Eriguchi M, Ikeuchi T, Uchida H. Establishment and characterization of human pancreatic adeno-carcinoma cell line SOJ producing carcinoembryonic antigen and carbohydrate antigen 19-9. Human Cell 1990; 3:31-6.
18. Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. Eur J Pharmacol 2006; 540:34-45.
19. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 2000; 97:12513-8.
20. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res 1988; 22:10881-90.
21. Ehrenberg B, Montana V, Wei MD, Wuskell JP, Loew LM. Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes. Biophys J 1988; 53:785-94.
22. Scaduto JrRC, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999; 76:469-77.
23. Nicoletti I, Migliorati G, Pagliacei MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
24. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabin. Biochemica et Biophysica Acta 2007; 1773:1095-106.
25. Vermes I, Haanen H, Steffens Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometry detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Mehods 1995; 184:39-51.
26. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Comm 2006; 348:1245-53.
27. WAF1/Cip1 and Gelsolin. Cancer Res 2000; 60:6068-74.
28. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylase. Cell Mol Life Sci 2003; 60:1990-7.
29. Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of mall-molecule inhibitors. Chem Biol 2002; 9:3-16.
30. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-egger C, Henklein P, Frye R, McBurney MW, Hruby H, Jung M, Verdin E, Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. PLOS Biol 2005; 3:0210-20.